Control of experimental spasticity by targeting the degradation of endocannabinoids using selective fatty acid amide hydrolase inhibitors

Multiple Sclerosis Journal

Volumn 19, Issue 14, 2013, Pages 1896-1904

  Pryce, G ^a   Cabranes, A ^b   Fernandez Ruiz J ^b,c   Bisogno, T ^d,e   Di Marzo, V ^d   Long, J Z ^f   Cravatt, B F ^f   Giovannoni, G ^a   Baker, D ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^d CNR   (Italy)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

^f SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Anandamide; endocannabinoid; experimental autoimmune encephalomyelitis; fatty acid amide hydrolase; multiple sclerosis; spasticity

Indexed keywords

ANANDAMIDE; CAY 100400; CAY 100402; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; FATTY ACID AMIDASE INHIBITOR; JZL 184; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; BRAIN CORTEX; CEREBELLUM; DRUG DEGRADATION; DRUG INHIBITION; FEMALE; HIPPOCAMPUS; IN SITU HYBRIDIZATION; MALE; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; RECEPTOR DENSITY; RECEPTOR GENE; SPASTICITY;

ANANDAMIDE; ENDOCANNABINOID; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FATTY ACID AMIDE HYDROLASE; MULTIPLE SCLEROSIS; SPASTICITY;

AMIDOHYDROLASES; ANIMALS; ARACHIDONIC ACIDS; BRAIN; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENDOCANNABINOIDS; ENZYME INHIBITORS; FEMALE; MALE; MICE; MICE, BIOZZI; MICE, KNOCKOUT; MOLECULAR TARGETED THERAPY; MONOACYLGLYCEROL LIPASES; MUSCLE SPASTICITY; MUSCLE, SKELETAL; POLYUNSATURATED ALKAMIDES; TIME FACTORS;

EID: 84888622971     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458513485982     Document Type: Article

References (35)

1. Baker D, Pryce G, Jackson SJ, et al. The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis. Mult Scler Rel Dis. 2012 ; 1: 64-75
2. Baker D, Pryce G, Croxford JL, et al. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature. 2000 ; 404: 84-87
3. Baker D, Pryce G, Croxford JL, et al. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J. 2001 ; 15: 300-302
4. Katona I, Freund TF.. Multiple functions of endocannabinoid signaling in the brain. Ann Rev Neurosci. 2012 ; 35: 529-558
5. Novotna A, Mares J, Ratcliffe S, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®)), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol. 2011 ; 18: 1122-1131
6. Corey-Bloom J, Wolfson T, Gamst A, et al. Smoked cannabis for spasticity in multiple sclerosis: A randomized, placebo-controlled trial. CMAJ. 2012 ; 184: 1143-1150
7. Zajicek JP, Hobart JC, Slade A, et al. Multiple sclerosis and extract of cannabis: Results of the MUSEC trial. J Neurol Neurosurg Psychiatry. 2012 ; 83: 1125-1132
8. Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): Multicentre randomised placebo-controlled trial. Lancet. 2003 ; 362: 1517-1526
9. Cravatt BF, Demarest K, Patricelli MP, et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci U S A. 2001 ; 98: 9371-9376
10. Leung D, Saghatelian A, Simon GM, et al. Inactivation of N-acyl phosphatidylethanolamine phospholipase D reveals multiple mechanisms for the biosynthesis of endocannabinoids. Biochemistry. 2006 ; 45: 4720-4526
11. Blankman JL, Simon GM, Cravatt BF.. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol. 2007 ; 14: 1347-1356
12. Long JZ, Li W, Booker L, et al. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol. 2009 ; 5: 37-44
13. Schlosburg JE, Blankman JL, Long JZ, et al. Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Nat Neurosci. 2010 ; 13: 1113-1119
14. Eljaschewitsch E, Witting A, Mawrin C, et al. The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron. 2006 ; 49: 67-79
15. Glaser ST, Abumrad NA, Fatade F, et al. Evidence against the presence of an anandamide transporter. Proc Natl Acad Sci U S A. 2003 ; 100: 4269-4274
16. Ortega-Gutiérrez S, Hawkins EG, Viso A, et al. Comparison of anandamide transport in FAAH wild-type and knockout neurons: Evidence for contributions by both FAAH and the CB1 receptor to anandamide uptake. Biochemistry. 2004 ; 43: 8184-8190
17. Fu J, Bottegoni G, Sasso O, et al. A catalytically silent FAAH-1 variant drives anandamide transport in neurons. Nat Neurosci. 2011 ; 15: 64-69
18. Kaczocha M, Vivieca S, Sun J, et al. Fatty acid-binding proteins transport N-acylethanolamines to nuclear receptors and are targets of endocannabinoid transport inhibitors. J Biol Chem. 2012 ; 287: 3415-3424
19. Fowler CJ.. Transport of endocannabinoids across the plasma membrane and within the cell. FEBS J. 2013 ;:
20. Pryce G, Baker D.. Control of spasticity in a multiple sclerosis model is CB1, not CB2, cannabinoid receptor mediated. Brit J Pharmacol. 2007 ; 150: 519-525
21. Pertwee RG, Howlett AC, Abood ME, et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: Beyond CB1 and CB2. Pharmacol Rev. 2010 ; 62: 588-631
22. Al-Izki S, Pryce G, O'Neill JK, et al. Practical guide to the induction of relapsing progressive experimental autoimmune encephalomyelitis in the Biozzi ABH mouse. Mult Scler Rel Dis. 2012 ; 1: 29-38
23. Marsicano G, Wotjak CT, Azad SC, et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature. 2002 ; 418: 530-534
24. Cabranes A, Pryce G, Baker D, et al. Changes in CB1 receptors in motor-related brain structures of chronic relapsing experimental allergic encephalomyelitis mice. Brain Res. 2006 ; 1107: 199-205
25. Boger DL, Sato H, Lerner AE, et al. Exceptionally potent inhibitors of fatty acid amide hydrolase: The enzyme responsible for degradation of endogenous oleamide and anandamide. Proc Natl Acad Sci U S A. 2000 ; 97: 5044-5049
26. Kathuria S, Gaetani S, Fegley D, et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med. 2003 ; 9: 76-81
27. Boger DL, Miyauchi H, Du W, et al. Discovery of a potent, selective, and efficacious class of reversible alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as analgesics. J Med Chem. 2005 ; 48: 1849-1856
28. Huggins JP, Smart TS, Langman S, et al. An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee. Pain. 2012 ; 153: 1837-1846
29. Fegley D, Gaetani S, Duranti A, et al. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): Effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther. 2005 ; 313: 352-358
30. Kinsey SG, Wise LE, Ramesh D, et al. Repeated low dose administration of the monoacylglycerol lipase inhibitor JZL184 retains CB1 receptor mediated antinociceptive and gastroprotective effects. J Pharmacol Exp Ther. 2013 ;:
31. Okine BN, Norris LM, Woodhams S, et al. Lack of effect of chronic pre-treatment with the FAAH inhibitor URB597 on inflammatory pain behaviour: Evidence for plastic changes in the endocannabinoid system. Br J Pharmacol. 2012 ; 167: 627-640
32. Pryce G, Ahmed Z, Hankey DJ, et al. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain. 2003 ; 126: 2191-2202
33. Webb M, Luo L, Ma JY, et al. Genetic deletion of fatty acid amide hydrolase results in improved long-term outcome in chronic autoimmune encephalitis. Neurosci Lett. 2008 ; 439: 106-110
34. Graves RS, Pryce G, Cabranes A, et al. Fatty acid amide hydrolase as a target for neuroprotection. Mult Scler J. 2011 ; 17: S431
35. Croxford JL, Pryce G, Jackson SJ, et al. Cannabinoid-mediated neuroprotection, not immunosuppression, may be relevant to multiple sclerosis. J Neuroimmunol. 2008 ; 193: 120-129